



## PARKINSON'S DISEASE NEWS

<http://www.viartis.net/parkinsons.disease/news.htm>

18th April 2012 - News release

### LEVODOPA-CARBIDOPA INTESTINAL GEL CLINICAL TRIAL RESULTS

Abbott's have announced the results of the Phase 3 clinical trial in the U.S.A. of their investigational treatment for advanced Parkinson's Disease. The treatment involved levodopa-carbidopa intestinal gel (LCIG). The treatment is already approved in many countries outside the U.S.A. as Duodopa. LCIG contains the same active medication as Sinemet, which is levodopa-carbidopa IR tablets. LCIG was administered using a procedurally-implanted tube connected to a portable pump that delivers the medication directly into the small intestine, where it is absorbed into the bloodstream, providing a continuous delivery of medication during the 16 hours a day of pump use.

Participants had had Parkinson's Disease for an average of over 10 years, and experienced an average of over 6 hours "off" time. Their average "off" time decreased by 4 hours per day with LCIG, which was 1.9 fewer hours of "off" time compared to levodopa-carbidopa IR in tablet form. Adverse events occurred in 95% of people on LCIG, and 100% of people on levodopa-carbidopa IR tablets. The most common adverse events were complication of device insertion (51%), abdominal pain (42%), procedural pain (32%), nausea (25%), constipation (21%), orthostatic hypotension (18%), post-operative wound infection (17%), and incision site erythema (16%). Treatment-related serious adverse events were reported in 14% of the LCIG patients, and 21% of the levodopa-carbidopa IR tablet patients. For more information go to the News release :

<http://www.abbott.com/news-media/press-releases/abbotts-investigational-treatment-for-advanced-parkinsons-disease-demonstrates-positive-results.htm>

<http://www.viartis.net/parkinsons.disease/news/120409.pdf>  
mail@viartis.net

©2012 Viartis